Top

Published in:

01-10-2024 | Lung Cancer | Review

Risk factors for cancer-related cognitive impairment among individuals with lung cancer: a systematic review and meta-analysis

Authors: Lei Ye, Xiaoyu Xu, Wei Qi, Fangmei Chen, Guanghui Xia

Published in: Supportive Care in Cancer | Issue 10/2024

Abstract

Objectives

Cancer-related cognitive impairment (CRCI) exerts a negative impact on the quality of life in lung cancer survivors. Risk factors for CRCI in lung cancer patients remain unclear.This study aimed to identify risk factors for CRCI in lung cancer patients.

Methods

A comprehensive literature search was conducted across PubMed, CINAHL, Web of Science, Wanfang, VIP Database, Embase, and China National Knowledge Infrastructure (CNKI) from their inception until March 10, 2024. Studies were screened, data extracted, and quality assessed using the Agency for Healthcare Research and Quality and Newcastle–Ottawa Scale. Meta-analysis was performed using RevMan 5.4, assessing risk factors through odds ratios (OR) with 95% confidence intervals (CIs).

Results

The analysis was comprised of nine studies, including 1,305 patients. Seven studies were high quality, and two were moderate quality. Identified risk factors for CRCI in lung cancer patients included advanced age (OR = 3.51, 95%CI: 2.14–5.74, I² = 0.0%), cranial irradiation (OR = 2.12, 95% CI: 1.39–3.22, I² = 0.0%), anxiety (OR = 2.92, 95% CI: 1.65–5.25, I² = 37%), and symptom cluster burden (OR = 4.85, 95% CI: 2.99–7.87, I² = 0.0%). Physical activity (OR = 0.37, 95% CI; 0.23–0.58, I² = 9.0%) was identified as a protective factor.

Conclusion

Advanced age, cranial irradiation, anxiety, and symptom cluster burden are significant risk factors for CRCI, while physical activity serves as a protective factor. These insights provide healthcare professionals with an evidence-based framework for managing CRCI in lung cancer patients.

Available only for authorised users

Li J, Li C, Puts M et al (2023) Effectiveness of mindfulness-based interventions on anxiety, depression, and fatigue in people with lung cancer: A systematic review and meta-analysis. Int J Nurs Stud 140:104447. https://doi.org/10.1016/j.ijnurstu.2023.104447PubMedCrossRef

Simó M, Root JC, Vaquero L et al (2015) Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 10:38–45. https://doi.org/10.1097/JTO.0000000000000345CrossRef

Welzel T, Niethammer A, Mende U et al (2008) Diffusion tensor imaging screening of radiation-induced changes in the white matter after prophylactic cranial irradiation of patients with small cell lung cancer: first results of a prospective study. AJNR Am J Neuroradiol 29:379–383. https://doi.org/10.3174/ajnr.A0797PubMedPubMedCentralCrossRef

Grosshans DR, Meyers CA, Allen PK et al (2008) Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation. Cancer 112:589–595. https://doi.org/10.1002/cncr.23222PubMedCrossRef

Bartels F, Wandrey M-M, Aigner A et al (2021) Association between neuronal autoantibodies and cognitive impairment in patients with lung cancer. JAMA Oncol 7:1302–1310. https://doi.org/10.1001/jamaoncol.2021.2049PubMedPubMedCentralCrossRef

Gregor A, Drings P, Burghouts J et al (1997) Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European organization for research and treatment of cancer lung cancer cooperative group study. J Clin Oncol Off J Am Soc Clin Oncol 15:2840–2849. https://doi.org/10.1200/JCO.1997.15.8.2840CrossRef

Lange M, Joly F, Vardy J et al (2019) Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol Off J Eur Soc Med Oncol 30:1925–1940. https://doi.org/10.1093/annonc/mdz410CrossRef

Ho M-H, So TW, Fan CL et al (2024) Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis. Supp Care Cancer Off J Multinatl Assoc Support Care Cancer 32:209. https://doi.org/10.1007/s00520-024-08402-9CrossRef

Schagen SB, Tsvetkov AS, Compter A, Wefel JS (2022) Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nat Rev Neurol 18:173–185. https://doi.org/10.1038/s41582-021-00617-2PubMedCrossRef

10.

Zeng Y, Dong J, Huang M et al (2020) Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. Int J Nurs Stud 104:103514. https://doi.org/10.1016/j.ijnurstu.2019.103514PubMedCrossRef

11.

Cheng ASK, Wang X, Niu N et al (2022) Neuropsychological interventions for cancer-related cognitive impairment: a network meta-analysis of randomized controlled trials. Neuropsychol Rev 32:893–905. https://doi.org/10.1007/s11065-021-09532-1PubMedCrossRef

12.

van der Weijst L, Lievens Y, Surmont V, Schrauwen W (2022) Neurocognitive functioning following lung cancer treatment: The PRO-Long Study. Tech Innov Patient Support Radiat Oncol 21:36–40. https://doi.org/10.1016/j.tipsro.2022.02.004PubMedPubMedCentralCrossRef

13.

Brautiga L, Nl Hill NI (2022) Promoting cognitive health in older adult cancer survivors. J Gerontol Nurs 48. https://doi.org/10.3928/00989134-20211206-01

14.

Liu Y, Li R-L, Chen L et al (2024) Construction and validation of a risk-prediction model for chemotherapy-related cognitive impairment in patients with breast cancer. J Cancer Surviv Res Pract. https://doi.org/10.1007/s11764-024-01566-7CrossRef

15.

Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S (2017) Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol 13:52–64. https://doi.org/10.1038/nrneurol.2016.185PubMedCrossRef

16.

Henneghan A (2016) Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 24:481–497. https://doi.org/10.1007/s00520-015-2927-yCrossRef

17.

Zhou X, Zhang X, Zhong T et al (2024) Prevalence and associated factors of chemotherapy-related cognitive impairment in older breast cancer survivors. J Adv Nurs 80:484–499. https://doi.org/10.1111/jan.15842PubMedCrossRef

18.

Jesús O-J, Luis C-P, Matilde M-F (2023) Effects of exercise on cancer-related cognitive impairment in breast cancer survivors: a scoping review. Breast Cancer Tokyo Jpn 30:885–909. https://doi.org/10.1007/s12282-023-01484-zCrossRef

19.

Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708. https://doi.org/10.1016/S1470-2045(10)70294-1PubMedCrossRef

20.

Takemura N, Ho M-H, Cheung DST, Lin C-C (2022) Factors associated with perceived cognitive impairment in patients with advanced lung cancer: a cross-sectional analysis. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 30:9607–9614. https://doi.org/10.1007/s00520-022-07377-9CrossRef

21.

Eggen AC, Richard NM, Bosma I et al (2022) Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. Neuro-Oncol Pract 9:50–58. https://doi.org/10.1093/nop/npab056CrossRef

22.

Lo CK-L, Mertz D, Loeb M (2014) Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 14:45. https://doi.org/10.1186/1471-2288-14-45PubMedPubMedCentralCrossRef

23.

Viswanathan M, Ansari MT, Berkman ND, et al (2008) Assessing the risk of bias of individual studies in systematic reviews of health care interventions. In: methods guide for effectiveness and comparative effectiveness reviews. Agency for Healthcare Res Qual (US), Rockville (MD)

24.

Wang QX (2019) Analysis of cognitive function and quality of life in 64 lung cancer patients with non-brain metastases. Dissertation, Suzhou University

25.

Zhen JJ, Peng ZR, Li SQ, et al (2019) Analysis of neurocognitive functions in patients with brain metastasis of lung cancer. Guangdong medic J 40:50–54. https://doi.org/10.13820/j.cnki.gdyx.20185298

26.

Soria-Comes T, Palomar-Abril V, Martín Ureste M, et al (2020) Cognitive impairment is related to a reduced count of T-lymphocytes in older patients diagnosed with non-small cell lung cancer (NSCLC). Transl Cancer Res 9:6857–6866. https://doi.org/10.21037/tcr-20-1997

27.

Li H, Ding X, He HM, Ma LH (2021) Analysis of influencing factors of neurocognitive impairment after chemotherapy of lung cancer and its correlation with quality of life. J Clinic and Experimental Medic 20:1191–1195

28.

Zeng H, Hendriks LEL, Witlox WJA et al (2023) Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 study. Radiother Oncol J Eur Soc Ther Radiol Oncol 183:109627. https://doi.org/10.1016/j.radonc.2023.109627CrossRef

29.

Wang SH, Min XH, Song B et al (2023) Influencing factors of cognitive function and quality of life in patients with non-small cell lung cancer. J Clinic Pulmonary Sci 28:843–847

30.

Luo J, Liu R, Luo Y et al (2023) The high burden of symptoms associated with cognitive impairment in lung cancer patients: a latent class analysis. Asia-Pac J Oncol Nurs 10:100200. https://doi.org/10.1016/j.apjon.2023.100200PubMedPubMedCentralCrossRef

31.

Vega JN, Dumas J, Newhouse PA (2017) Cognitive effects of chemotherapy and cancer-related treatments in older adults. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry 25:1415–1426. https://doi.org/10.1016/j.jagp.2017.04.001CrossRef

32.

Reale ML, Romano GD, Paolelli L, Leo S (2023) Checkpoint inhibitors in older patients with advanced non-small cell lung cancer. Crit Rev Oncol Hematol 188:104056. https://doi.org/10.1016/j.critrevonc.2023.104056PubMedCrossRef

33.

Loh KP, Janelsins MC, Mohile SG et al (2016) Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol 7:270–280. https://doi.org/10.1016/j.jgo.2016.04.008PubMedPubMedCentralCrossRef

34.

Frank MS, Bodtger U (2023) An individualized approach to comorbidities in lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 18:254–256. https://doi.org/10.1016/j.jtho.2022.12.007CrossRef

35.

Olson B, Marks DL (2019) Pretreatment cancer-related cognitive impairment-mechanisms and outlook. Cancers 11:687. https://doi.org/10.3390/cancers11050687PubMedPubMedCentralCrossRef

36.

Lung Cancer Specialty Committee of Chinese Elderly Health Care Association, Lung Cancer Specialty Committee of Beijing Cancer Society (2022) [consensus of chinese experts on medical treatment of advanced lung cancer in the elderly (2022 Edition)]. Zhongguo Fei Ai Za Zhi Chin J Lung Cancer 25:363–384. https://doi.org/10.3779/j.issn.1009-3419.2022.101.25

37.

Bade BC, Faiz SA, Ha DM et al (2023) Cancer-related fatigue in lung cancer: a research agenda: an official american thoracic society research statement. Am J Respir Crit Care Med 207:e6–e28. https://doi.org/10.1164/rccm.202210-1963STPubMedPubMedCentralCrossRef

38.

Wang Y-H, Li J-Q, Shi J-F et al (2020) Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry 25:1487–1499. https://doi.org/10.1038/s41380-019-0595-xPubMedCrossRef

39.

Gleeson M, Bishop NC, Stensel DJ et al (2011) The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11:607–615. https://doi.org/10.1038/nri3041PubMedCrossRef

40.

Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical Trial. JAMA 316:401–409. https://doi.org/10.1001/jama.2016.9839PubMedPubMedCentralCrossRef

41.

Rodríguez de Dios N, Couñago F, Murcia-Mejía M et al (2021) Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): A GICOR-GOECP-SEOR study. J Clin Oncol Off J Am Soc Clin Oncol 39:3118–3127. https://doi.org/10.1200/JCO.21.00639CrossRef

42.

Aupérin A, Arriagada R, Pignon JP et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med 341:476–484. https://doi.org/10.1056/NEJM199908123410703PubMedCrossRef

43.

Kirkman MA, Day J, Gehring K, et al (2022) Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev 11:CD011335. https://doi.org/10.1002/14651858.CD011335.pub3

44.

Zeng H, Hendriks LEL, van Geffen WH et al (2020) Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: a systematic review. Cancer Treat Rev 88:102025. https://doi.org/10.1016/j.ctrv.2020.102025PubMedCrossRef

45.

Myers JS (2009) A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function. Oncol Nurs Forum 36:E1-10. https://doi.org/10.1188/09.ONF.E1-E10PubMedCrossRef

46.

Marchant NL, Howard RJ (2015) Cognitive debt and Alzheimer’s disease. J Alzheimers Dis JAD 44:755–770. https://doi.org/10.3233/JAD-141515PubMedCrossRef

47.

Karim HT, Ly M, Yu G et al (2021) Aging faster: worry and rumination in late life are associated with greater brain age. Neurobiol Aging 101:13–21. https://doi.org/10.1016/j.neurobiolaging.2021.01.009PubMedPubMedCentralCrossRef

48.

Sedgwick P, Marston L (2015) How to read a funnel plot in a meta-analysis. BMJ 351:h4718. https://doi.org/10.1136/bmj.h4718PubMedCrossRef

49.

Myers JS, Erickson KI, Sereika SM, Bender CM (2018) Exercise as an Intervention to mitigate decreased cognitive function from cancer and cancer treatment: an integrative review. Cancer Nurs 41:327–343. https://doi.org/10.1097/NCC.0000000000000549PubMedPubMedCentralCrossRef

Title: Risk factors for cancer-related cognitive impairment among individuals with lung cancer: a systematic review and meta-analysis
Authors: Lei Ye
Xiaoyu Xu
Wei Qi
Fangmei Chen
Guanghui Xia
Publication date: 01-10-2024
Publisher: Springer Berlin Heidelberg
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Anxiety
Published in: Supportive Care in Cancer / Issue 10/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-024-08873-w

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

17-09-2024
Prostate Cancer
News

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

19-09-2024
Diagnostics in Oncology
News

No OS benefit of adding preoperative CRT in gastric cancer

17-09-2024
Gastric Cancer
News

T-DXd supported for breast cancer with brain metastases

17-09-2024
Breast Cancer
News

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Risk factors for cancer-related cognitive impairment among individuals with lung cancer: a systematic review and meta-analysis

Abstract

Objectives

Methods

Results

Conclusion

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2024

Inadequate management of opioid-induced constipation in European cancer pain patients: results of a real-world, multicentre, observational study (“E-StOIC”)

Identifying correlations between nutritional impact symptoms and risk factors for malnutrition in adult cancer patients with solid tumors: a cross-sectional study from a developing country

Non-gastrointestinal symptom burden following colorectal cancer treatment—a systematic review

Caring through uncertainty: a qualitative exploration of older colorectal cancer caregivers’ experiences during palliative chemotherapy

Is it really over when it is over? physical, mental and emotional health status of long-term breast cancer survivors compared to healthy matched controls

Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma